Enhancing [ 177 Lu]Lu-DOTA-TATE therapeutic efficacy in vitro by combining it with metronomic chemotherapeutics
Background: Peptide receptor radionuclide therapy (PRRT) uses [177Lu]Lu-[DOTA0-Tyr3]octreotate ([177Lu]Lu-DOTA-TATE) to treat patients with neuroendocrine tumours (NETs) overexpressing the somatostatin receptor 2A (SSTR2A). It has shown significant short-term improvements in survival and symptom all...
Autori principali: | Cheng, J, Zink, J, O’Neill, E, Cornelissen, B, Nonnekens, J, Livieratos, L, Terry, SYA |
---|---|
Natura: | Journal article |
Lingua: | English |
Pubblicazione: |
SpringerOpen
2024
|
Documenti analoghi
Documenti analoghi
-
Imaging DNA damage repair in vivo following 177Lu-DOTATATE therapy
di: O'Neill, E, et al.
Pubblicazione: (2019) -
Impact of cyclic changes in pharmacokinetics and absorbed dose in pediatric neuroblastoma patients receiving [177Lu]Lu-DOTATATE
di: Malcolm, J, et al.
Pubblicazione: (2022) -
Investigations towards a rational combination of 177Lu-PSMA with immunotherapy
di: Kramer, C
Pubblicazione: (2023) -
Impact of per-cycle changes in spatial and temporal pattern of dose and biokinetics in neuroblastoma patients receiving 177Lu-DOTATATE
di: Malcolm, J
Pubblicazione: (2019) -
In conversation with Xin Lu
di: Howe, FS, et al.
Pubblicazione: (2020)